Growth

CJC-1295 NO DAC

GHRH analogue · Non-acylated · 29 amino acids

FDA · CATEGORY 2 (2023)

Half-life

~30 minutes

Very short

minsdays

Route

SubQ injection

Evidence

Early human data

Risk

Standard

Dave Asprey Dave AspreyBiohacker · Podcaster · Bulletproof Founder

CJC-1295 is one of the most effective tools I've found for optimising growth hormone without suppressing your own axis.

BPC-157BPC-157GutHealing

Reference only — not an endorsement.

Overview

Known for

Growth hormone releasing hormone (GHRH) analogue. Short half-life (~30 min). Creates GH pulses rather than sustained elevation. Safer than exogenous HGH as it works with the body's natural feedback loop.

Mechanism

Modified GHRH analog (also called Mod GRF 1-29). Signals pituitary to release GH in natural pulsatile pattern. Does NOT flatten GH rhythm.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
SecretagogueSecretagogue
FDA category
Category 2 (2023)

Evidence & standing

Evidence base
Early human data
Risk level
Standard
Best studies
5 references
  • Teichman et al. (2006) J Clin Endocrinol Metab 91:799-805 — Pharmacokinetics in humans
  • Alba et al. (2006) JCEM 91:1477-82 — GH/IGF-1 response
  • NOT FDA APPROVED
  • One death reported in clinical trial (unrelated per investigators)
  • FDA Category 2 bulk drug substance (2023)

Dosage & protocol

Typical dose
100mcg
Research range
100–300 µg
Cycle
Daily (night)
Onset
21 days first effects
Full effect
70 days
Half-life
~30min
~30 minutes (short-acting, mimics natural pulse)
Protocol

100mcg per injection, 2-3x daily. Must be fasted. Before bed is the priority dose.

Time to effects

EARLY: 2-4 weeks

FULL: 8-12 weeks

Week 1-2: Improved sleep quality (especially with bedtime dose). Vivid dreams are common.

Week 2-4: Better recovery, increased energy. Subtle skin improvements.

Week 4-8: Fat loss begins, especially around midsection. Improved muscle tone.

Week 8-12: Cumulative GH benefits — body composition, skin, recovery all noticeably improved.

Much more effective when paired with Ipamorelin. Minimum commitment: 8 weeks.

Recommended vial
  • 5mg vials

At 300mcg/day, 5mg = ~17 days ✓. 10mg = 33 days (within 6-week window ✓). 5mg is the sweet spot.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
Side effects

Flushing (15-20%), headache, dizziness, injection site reaction, possible transient hypoglycaemia

Interactions

Somatostatin analogs (antagonize — cancel effect), glucocorticoids (↓GH response), insulin

Do not combine
CJC-1295 DACCJC-1295 DAC CJC-1295 NO DAC 5mg + Ipamorelin 5mg (Blend)CJC-1295 NO DAC 5mg + Ipamorelin 5mg (Blend) HGH 191 AA (97%)HGH 191 AA (97%) Sermorelin AcetateSermorelin Acetate TesamorelinTesamorelin

Handle with research caution

  • Do NOT combine with exogenous HGH (HGH suppresses pituitary, making secretagogues pointless)
  • Do NOT combine with CJC-1295 DAC (same receptor — use one or the other, not both)

Storage & handling

Lyophilised
12–24 months
room temp (stable)
Reconstituted
4–6 weeks
2–8°C